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57 ABSTRACT 
This invention relates to the isolation, identification and 
Sequencing of a cancer associated protein, preparation of 
hybridization probes therefrom, preparation of antibodies 
thereto, and methods of cancer risk assessment and diagno 
SS. 
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TUMIOR MARKER PROTEIN FOR CANCER 
RISKASSESSMENT 
RELATED APPLICATION 
The present application is a continuation-in-part of U.S. 
patent application Ser. No. 08/236,547, filed May 2, 1994, 
abandoned, which was a divisional application of U.S. 
patent application Ser. No. 08/012,972, filed Feb. 2, 1993, 
issued as a U.S. Pat. No. 5,310,653 on May 10, 1994, which 
was a continuation of U.S. patent application Ser. No. 
07/426,408, filed Oct. 24, 1989, abandoned. 
GOVERNMENT RIGHTS 
The United States Government may have certain rights to 
this invention pursuant to National Institutes of Health 
grants RR 5511-23 and CA54296. 
FIELD OF THE INVENTION 
This invention relates to the isolation, identification and 
Sequencing of a cancer associated protein, preparation of 
hybridization probes therefrom, preparation of antibodies 
thereto, and methods of cancer risk assessment and diagno 
SS. 
BACKGROUND OF THE INVENTION 
In Spite of improved treatments for certain forms of 
cancer, it is still a leading cause of death in the United States. 
Since the chance for complete remission of cancer is, in 
most cases, greatly enhanced by early diagnosis, it is very 
desirable that physicians be able to detect cancers before a 
Substantial tumor develops. Also, in cases where the primary 
tumor has been Substantially removed by Surgery or 
destroyed by other means, it is important that the physician 
be capable of detecting any trace of cancer in the patient 
(either in the form of residues of the primary tumor or of 
Secondary tumors caused by metastasis), in order that the 
physician can prescribe appropriate Subsequent treatment, 
Such as chemotherapy. 
The quantities of cancer cells that must be detected for 
early diagnosis or following removal or destruction of the 
primary tumor are So Small that the physician cannot rely 
upon physical examination of the cancer Site. Moreover, in 
many cases the cancer Site is of course not Susceptible to 
direct visual observation and it is almost always impractical 
to detect Secondary tumors by Visual observation, Since it is 
not possible to predict exactly where they are likely to occur. 
Accordingly, Sensitive tests have to rely upon detection of 
cancer-associated materials, usually proteins, present in 
body fluids of patients who have, or are about to develop, 
cancer cells in their bodies. Several diagnostic materials for 
detection of cancer-associated proteins are available com 
mercially. Tests for alpha-fetoprotein are used to detect 
primary liver cancer and teratocarcinoma in humans, and 
carcinoembryonic antigen is used for digestive System 
cancers, as well as lung and breast carcinomas, chorionic 
gonadotropin is employed to detect trophoblast and germ 
cell cancers, calcitonin is used for thyroid gland cancers, and 
prostatic acid phosphatase or prostate Specific antigen are 
used to detect prostate carcinoma. These markers are detect 
able in advanced rather than in early cancer. 
Unfortunately, many of the commercially available tests 
are only applicable to a narrow range of cancer types, and 
therefore these tests Suffer not only from the disadvantage 
that other types of cancer may be missed but also from the 












that it may be necessary to run multiple tests on a Single 
patient for diagnostic purposes, a procedure which not only 
increases the expense of the diagnostic testing but also 
increases the risk that one or other of the tests may give a 
false positive result. Accordingly, there is a need for a single 
diagnostic test able to detect the presence of very Small 
amounts of cells of a wide variety of different cancers. The 
ideal marker would be one that is specific and universal. 
Such a marker may exist if malignant transformation is 
asSociated with the expression of a unique gene product in 
all kinds of transformed cells. 
It is already known that serum from the blood of animals 
Suffering from a wide variety of cancers contains an oncofe 
tal protein having a molecular weight of approximately 
60,000 and having the capacity to increase the release of 
ribonucleic acid (RNA) from cell nuclei. This protein is 
referred to as oncofetal RNA-transport protein (ORTP) or 60 
kDa cancer-associated protein. 
ORTP is localized in the cytoplasm of tumors of humans 
and experimental animals and Small amounts are released 
into the host circulatory system. The 60 kDa ORTP is 
notably absent from the nuclei of rat liver and rat liver 
tumors. It has been shown to be present in fetal rats at 18 
days of gestation and in human and rat amniotic fluid, but 
not in maternal blood. It has not been detected in adult rats. 
Nor is it present in detectable concentrations in the blood of 
normal human Subjects or those with a variety of non 
neoplastic conditions or diseases, including benign tumors 
and other non-neoplastic proliferative diseases. In contrast, 
of more than 200 cancer patients with confirmed active 
disease, all tested positive for the factor. It was also present 
in all of about 200 tumor-bearing rats tested. Unfortunately, 
antibodies to a rat ORTP preparation purified as described in 
the prior art do not cross-react with human ORTP. Thus, the 
60 kDa cancer marker proteins from different Species are not 
immunologically equivalent, e.g., an antibody to the rat 
cancer marker protein does not croSS-react with a human 
cancer marker protein. Thus, when the purified 60 kDa 
cancer marker protein preparation is to be used for produc 
tion of antibodies for diagnostic purposes, it is necessary to 
begin the preparation process with plasma from the Species 
in which the diagnosis is to be used. 
We have recently identified, characterized in terms of its 
physical properties, and Sequenced another oncofetal protein 
with a molecular weight of 65 kDa (p65) which exhibits 
certain properties which Strongly favor its candidacy as a 
general tumor marker, as well as a marker of cancer risk 
asSociated with the prolonged use of drugs, Such as andro 
genic and estrogenic hormones, that have tumor promotional 
potential. 
This newly isolated and sequenced 65 kDa oncofetal 
protein, termed p65, exhibits properties desirable for a 
marker of pre-malignant and malignant alterations. The p65 
protein is a novel protein that appears to have Some homol 
ogy to the Steroid receptor Superfamily of genes. Therefore, 
the p65 gene may belong to a family of genes which encode 
nuclear receptors, composed of Several domains important 
in hormone binding, DNA-binding, dimerization, and acti 
Vation of transcription for various hydrophobic ligands Such 
as Steroids, Vitamin D, retinoic acid and thyroid hormones. 
More support for this theory is evident by the discovery that 
the p65 protein is located in nuclei of tumor cells and has 
DNA-binding properties. Alterations in hormone receptors 
Such as estrogen (ER) and progesterone receptor (PR) may 
be of prognostic Significance in breast cancer; therefore, 
elucidation of whether p65 is related to ER or PR is of 
utmost importance. Elevated Serum levels of p65 are detect 
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able by ELISA in 90% of patients with stage I-IV of breast 
cancer and limited immunohistochemical Studies have 
shown nuclear and cytoplasmic expression in 80% of breast 
cancer biopsies. In depth study of the p65 protein is thus 
helpful in understanding the mechanisms by which hor 
mones and their respective receptorS regulate the metabo 
lism of normal and malignant breast and prostate cancer as 
well as other cancers. 
The present invention, Specifically the elucidation of 
p65's Sequence can be utilized for the detection, diagnosis 
and hopefully, the future treatment of breast, prostate, ova 
rian and possibly other cancers that relate to the Steroid 
receptor Superfamily of genes. 
SUMMARY OF THE INVENTION 
This invention provides a protein preparation containing 
a pure form of a newly discovered oncofetal cancer marker 
protein encoded by the nucleic acid sequence SEQ ID NO: 
1 and having the amino acid sequence of SEQ ID NO: 2. 
More specifically, the invention provides the Sequence of 
and methods of using the nucleic acid sequence SEOID NO: 
1 and the rat p65 cancer-associated protein having the amino 
acid sequence SEQ ID NO:2 for the preparation of hybrid 
ization probes and antibodies to be used for the detection of 
CCC. 
One embodiment of the present invention provides a 
nucleic acid molecule of less than 2200 base pairs in length 
coding for the rat p65 protein. An aspect of this embodiment 
provides the DNA segment comprising a Sequence region 
having the sequence of SEQ ID NO: 1. Another aspect 
provides the analogous RNA segment. And yet a further 
aspect provides the amino acid Sequence having the 
sequence of SEQ ID NO: 2. 
The invention also provides that the DNA segment com 
prising a sequence region having the Sequence of SEQ ID 
NO: 1 be placed under the control of a promoter. The DNA 
Segment can also be placed into a plasmid and additionally 
into a recombinant host cell. 
The present invention further provides a method of using 
the DNA segment having the sequence of SEQ ID NO: 1 to 
make the encoded rat p65 comprising: 
(a) preparing a recombinant vector in which the Sequence 
of SEQ ID NO: 1 is positioned under the control of a 
promoter; 
(b) introducing the recombinant vector into a host cell to 
form a recombinant host cell; 
(c) culturing the recombinant host cell under conditions 
effective to allow expression of the protein; and 
(d) collecting the expressed protein. 
The invention additionally provides a recombinant rat p65 
protein prepared by expressing the rat p65 protein in a 
recombinant host cell and purifying the protein. 
In another embodiment, the present invention provides a 
Sequence region complementary to a region of at least 10-14 
contiguous nucleotides of SEQ ID NO: 1. 
The invention further provides a method for detecting p65 
and oncofetal protein in a Sample of mammalian origin 
comprising: 
(a) obtaining nucleic acids from a sample Suspected of 
containing the p65 protein; 
(b) contacting the sample nucleic acids with a nucleic acid 
Segment of at least 10–14 nucleotide long continuous 
Sequence that is complementary to a contiguous 
sequence of SEQ ID NO: 1 under appropriate condi 











(c) detecting the hybridized nucleic acids thus formed. 
In one aspect of the aforementioned embodiment the 
Sample nucleic acids are located within a cell Such as in the 
case of in Situ hybridization. Alternatively, the Sample 
nucleic acids are Separated from a cell and then tested for the 
presence of a Sequence complementary to the 10-14 nucle 
otide long Sequence. The nucleic acids to be tested can be of 
DNA (Southern blotting) or RNA (Northern blotting). 
Finally, this invention provides a method for assessing the 
likelihood of cancer which involves immunoassays and 
hybridization assays to detect the presence of the instant p65 
tumor marker protein in biological material of a host Sus 
pected of developing cancer or being at high risk for 
developing cancer as the result of treatment with drug(s) 
known to have a tumor promotion potential. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows p65 tumor-associated protein production 
during 7,12-dimethylbenzajanthracene (DMBA)-induced, 
and 12-0-tetra-decanoylphorbol-13-acetate (TPA)-promoted 
skin carcinogenesis in SENCAR mice. 
FIG. 1A shows the time course of papilloma appearance 
following carcinogenesis promotion and FIG. 1B shows the 
time course of p65 accumulation in the blood plasma 
following the same carcinogenesis promotion. 
FIG. 2 shows enhancement by synthetic steroid hormone 
of p65 tumor-associated protein production during chemical 
carcinogenesis. 
FIG. 3 shows Zinc finger structure within p65. The amino 
acids abbreviated with three letters represent conserved 
regions of Zinc fingers among family members. 
DETAILED DESCRIPTION OF THE 
PREFERRED EMBODIMENTS 
Methods for Diagnosing or ASSessing the Likelihood of 
Cancer 
Samples of blood plasma or Serum tissue are obtained 
from human cancer patients or human Subjects prior to and 
at different times in the course of treatment with synthetic 
Steroid hormones or other drugs known or Suspected of 
having a tumor promotion potential. Alternatively, Samples 
of blood plasma, Serum or tissue are obtained from other 
mammals Suspected of Suffering from cancer or treated with 
Substances Suspected of causing cancer. 
Briefly, Samples of the blood plasma or Serum containing 
the same amount of protein are mixed with an electrophore 
sis sample buffer, boiled for three minutes and subjected to 
12.5% SDS-PAGE. Subsequently, the gel slabs are prepared 
for transfer by equilibrating for one hour in 0.025M Tris, 
0.192M glycine, 20% (v/v) methanol, pH 8.3, and then 
transblotted onto nitrocellulose sheets. To conduct the 
immunoassay, the nitrocellulose sheets are treated with 
appropriate blocking Solution to block unspecific binding 
Sites and incubated overnight, either with pre-immune Serum 
(controls) or antibody against the p65 protein diluted 1:200. 
Secondary biotinylated antibody is applied next and the 
color is developed using ABC Elite Kit from Vector 
Laboratories, Burlingame, Calif. The highly specific poly 
clonal antibody against p65 is obtained by immunizing 
rabbit with pure human or rat p65 preparations. AS an 
alternative, mouse monoclonal antibodies to p65 may be 
prepared using the techniques generally described in "Hybri 
doma Techniques” Cold Spring Harbor, N.Y., 1980, ISBN 
O-87969-143-3. 
The immunoblots are photographed and the bands of p65 
immune complexes on the film are quantitated using a laser 
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densitometer coupled to an integrator. Alternatively, follow 
ing probing with the antibodies to p65 or pre-immune Serum, 
nitrocellulose sheets are labeled with 'I-protein A. The 
labeled sheets are Subjected to autoradiography followed by 
Scanning the film with a laser densitometer coupled to an 
integrator. Another alternative is to use an ELISA procedure. 
To interpret the plasma or Serum or tissue Samples, the 
relative quantity of p65 in the Sample is indicated by the 
intensity of a band at nominal molecular weight about 
65,000 as measured by laser scanning. Comparison with the 
corresponding area of the control (derived with the use of 
pre-immune serum) permits distinguishing response specific 
for p65 above non-specific background response. Specific 
activity of the marker band from clinical Samples taken in 
the course of treatment is compared with the Samples taken 
prior to treatment and/or with the average Sample from a 
normal healthy pool. The clinical response can be then 
expressed as a factor against the response prior to treatment 
or against the response of the normal healthy pool, respec 
tively. Steady increases in the value of clinical response over 
a period of time are indicative of an increased cancer risk 
asSociated with the long-term treatment with a given Syn 
thetic Steroid or other drug that has tumor promotional 
properties. The high initial response is indicative of an 
existing cancer. 
EXAMPLE I 
Animal Models for Determination of the Presence of 
Cancer Cells 
This example illustrates the instant process for purifica 
tion of the p65 tumor-associated protein and preparation of 
antibodies thereto as source of p65. 
Rat and Mouse Liver Tumors 
Rathepatoma cell lines McA-RH7777 and McA-RH8994 
were purchased from the American Type Culture Collection 
(Rockville, Md.) and carried as cell cultures in Swim's S77 
medium with 4 mM L-glutamine and supplemented with 5% 
fetal calf serum and 20% horse serum (Gibco, Grand Island, 
N.Y.). After Several passages in cell culture, rat hepatoma 
cells (1x10/0.2 ml phosphate-buffered saline) were inocu 
lated Subcutaneously into a hind leg of male Buffalo rats 
(120-150 g) (Harlan Labs, Indianapolis, Ind.) and were 
carried as Solid tumors according to conventional proce 
dures. 
Transplantable hepatocellular carcinoma (THC) 1682C 
was derived from primary hepatic tumors in ACI rats 
maintained for four months on the choline-deficient diet of 
Shinozuka containing 0.2% ethionine and eight months on a 
choline-supplemented (0.8%) diet without ethionine. THC 
T52 was established by intraperitoneal transplantation of 
growing tumors induced in ACI rats by 
2-acetylaminofluorene (AAF). THC cultures were main 
tained in vitro and also carried as Solid (1682C) and ascitic 
(T52) tumors in male ACI rats (The University of Texas 
M.D. Anderson Cancer Center Science Park-Veterinary 
Resources Division, Bastrop, Tex.). 
The Reuber hepatoma cell culture H35 was provided by 
Dr. Andrew P. Butler, University of Texas M.D. Anderson 
Cancer Center Carcinogenesis Department, Science Park, 
Smithville, Tex. 
Mouse liver carcinoma CRL 6421 (formerly NBL 
#MM45T.Li) was obtained from American Type Culture 
Collection and carried as cell cultures as described above for 











Purification of p65 
Preparation of the antibody involves purification of the 
p65 marker protein from the tissue culture medium of tumor 
cells of human or animal origin. Specifically, the cells were 
grown to confluence at 37 C. in the presence of media and 
a Serum or Serum-like Supplement, or completely defined 
medium containing Salts and hormones. Growing cells to 
confluence was a purely economical Step which ascertains a 
high yield of the p65 marker protein. The preferred medium 
used was Dulbeccols Modified Eagle's Medium (DMEM) 
with 5% fetal calf serum and cells were grown in 5% CO. 
The confluent cells were washed three times in serum-free 
DMEM medium and incubated in this medium for 16-24 
hours (the optimal time being 24 hours). At this point, 
medium was collected by centrifugation at 10,000 x g for 
10-15 minutes and treated with ammonium Sulfate Solution 
at 90% saturation of aqueous solution for 30 minutes at 4 
C. 
Protein precipitate was collected by 30-minute centrifu 
gation at 10,000x g, dissolved in a small volume of 50 mM 
Tris-Cl buffer, pH 7.5, with 50 mM NaCl, 10 mM 
2-mercaptoethanol and 1 mM EDTA, and dialyzed over 
night against the same buffer. After dialysis, proteins were 
loaded on an LKBTSK3000 SW molecular sieving column 
and Separated according to the molecular weight using an 
LKB HPLC system. Fractions containing proteins with 
molecular weight in the range of 50-90 kDa were collected 
and dialyzed overnight against buffer A, containing 20% 
ammonium sulfate in 50 mM Tris-Cl, pH 7.5 with 10 mM 
2-mercaptoethanol and 1 mM EDTA. 
Following dialysis, the 50-90 kDa proteins were loaded 
on a phenyl hydrophobic interaction column (PHI) (LKB, 
Pharmacia) equilibrated with buffer A. Generally, 800-1,000 
ml of conditioned medium was processed as described 
above. The p65 marker protein weakly binds to the PHI 
column and is eluted in the first distinct peak by a gradient 
of 80% to 0% of buffer A, in combination with buffer B (50 
mM Tris-Cl, pH 7.5 with 10 mM 2-mercaptoethanol and 1 
mM EDTA, supplemented with 50% ethylene glycol). Frac 
tions containing the p65 marker protein are then combined 
and dialyzed against buffer A devoid of ammonium Sulfate, 
concentrated by lyophilization and electrophoresed on 
12.5% SDS-PAGE at constant current of a 10 mA for two 
hours at room temperature. 
Proteins are transblotted to a 0.22u nitrocellulose sheet as 
described by Towbin et al. (Proc. Natl. Acad. Sci. U.S.A., 
Vol. 76, pages 4350-4353, 1979). A reversible Ponceau. A 
Stain was used to visualize the nitrocellulose bound proteins 
according to the procedure of Salinovich and Montellaro 
(Anal. Biochem., Vol. 156, pages 341-347, 1986). The band 
of the p65 protein was cut out of the nitrocellulose sheets 
and used for immunization of rabbits. 
Mouse p65 was isolated from the mouse liver carcinoma 
cell line CRL 6421 (MM45) and purified as described above 
for the rat factor. 
Preparation of Antibodies to p65 
Antisera to the purified rat p65 preparation were raised in 
rabbits, as follows. 
Specific Pathogen Free (Pasteurella) male New Zealand 
white rabbits of approximately four kilograms body weight 
were used (Myrtle Is Rabbitry). Pre-immune (day 0) and test 
blood Samples (10 days following each of four immuniza 
tions on day 1, 14, 28 and 42) were obtained from the central 
artery of the ear or a lateral ear vein. The anesthetized rabbits 
were placed in Sternal recumbency, the dorsal fur was 
removed with Surgical clippers, and the Surgical site was 
aseptically prepared with provodine-iodine (Wescodyne, 
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West Chemical) followed by 70% ethanol. Six incisions 
about 1.0 cm each were made in an anteroposterior direction 
through the skin and Subcutis with a Scalpel. The incisions 
were undermined with blunt and sharp dissection to allow 
implant placement over the Superficial epaxial musculature. 
The nitrocellulose Strip containing the rat p65 protein was 
cut into six pieces (each approximately 0.5 cmx 1.5 cm) 
which were then formed into rolls for insertion. Following 
placement, the skin edges were opposed with tissue forceps 
and closed with surgical adhesive (Vetbond, 3M). Adequate 
spacing (about 2.5 cm) between insertion fields will allow 
Subsequent immunization incisions to be made adjacently. 
Terminal blood collection was made in Alsever's Solution in 
anesthetized rabbits by the use of a vacuum assisted collec 
tion device to provide the Serum which is the polyclonal 
antibody source. The antisera were absorbed with normal 
plasma proteins immobilized on nitrocellulose sheets fol 
lowing its electrophoresis on 10% SDS-PAGE and trans 
blotting. An ELISA assay or immunoblotting analysis was 
conducted to determine the potency and Specificity of the 
antisera obtained. 
A standard ELISA procedure was used for detection of 
Specific antibodies in Serum. Ninety-six well microliter 
plates designed for ELISA were used (Immunol 2, 
Dynatech). For detection of rabbit anti-p65 antibodies, the 
ELISA plates were pre-coated with several different con 
centrations of antigen. To test Sera, a positive reference 
Serum and a negative pre-immune Serum were added to the 
wells in five-fold dilutions in PBS. Anti-p65 antibodies were 
detected by goat anti-rabbit IgG conjugated with horse 
radish peroxidase (Bio-Rad). After the Substrate reaction, 
plates were read on an ELISA plate reader at 405 nm (Litton 
Bionetics, Laboratory Product Division, South Carolina). A 
serum sample was considered positive when it read 0.05 
units or more above the background. 
Probing of Western blots with prepared antibody was 
carried as follows. 
The purified rat tumor-associated protein, p65, was sepa 
rated by PAGE and electrophoretically transferred to nitro 
cellulose as described above. Free binding Sites on the 
nitro-cellulose sheets were then blocked overnight using 1% 
normal goat serum in TTBS buffer (0.5% Tween, 0.1 mM 
Tris-HCl, pH 7.1, 09% saline). Antisera obtained from 
immunized rabbits were diluted serially in the blot buffer 
(TTBS) and incubated with the nitro-cellulose strips for one 
hour at room temperature. The blots were then washed with 
several changes of TTBS buffer containing 1% goat serum. 
Bound antibody was detected using biotinylated Second 
antibody (goat anti-rabbit IgG, biotinylated) and the avidin 
biotin-peroxidase method (Vectastain ABC Elite, Vector, 
Burlingame, Calif.). To develop blots, 0.02% hydrogen 
peroxide was used, mixed with 0.1% diaminobenzidine 
tetrachloride (DAB) made in 0.1M Tris-HCl buffer, pH 7.2. 
Color generally developed within five to ten minutes; blots 
were rinsed with distilled water and air dried to preserve 
color. 
Alternatively, bound antibody was detected by incubating 
the nitrocellulose strips with 'I-Protein A (1x10 cpm/ml 
of blot buffer). After a 60-minute incubation, unbound label 
was removed by repeated washes of the blots with PBS 
buffer containing 0.5% Tween. The bound antigen 'I- 
Protein A complex was detected by overnight autoradiog 
raphy using Kodak X-OMATAR film. 
In addition, monoclonal antibody preparations can be 
made to the 65 kDa cancer marker by employing conven 













SDS-PAGE and Immunoblotting Analyses 
Carefully dissected hepatomas (see Example I) and liver 
fragments from normal rats and mice were rinsed with an 
ice-cold Saline Solution and processed for immunochemical 
determination of p65. Liver tumor cells grown in culture, as 
described in Example I, were Separated from medium by 
centrifugation, rinsed with the cold Saline Solution, and 
processed for immunoassay of the p65 tumor-associated 
factor. Briefly, Small pieces of tissueS or tumor cell pellets 
were homogenized in TMK-Sucrose buffer, pH 7.2, and 
Samples of the total homogenate containing the same 
amount of protein were mixed with electrophoresis Sample 
buffer, boiled for three minutes, and subjected to 10% 
SDS-PAGE. The proteins precipitated at 90% saturation of 
ammonium Sulfate from the conditioned medium of hepa 
tocarcinoma cells were dissolved in TMK buffer and elec 
trophoresed in a similar manner. Subsequently, the gel slabs 
were prepared for transfer by equilibration for one hour in 
0.025M Tris, 0.192M glycine, 20% methanol (vol/vol), pH 
8.3, and then transblotted onto nitrocellulose sheets. 
For immunoassay, the nitrocellulose sheets were treated 
with the appropriate blocking Solution to block non-specific 
binding sites and incubated overnight, either with pre 
immune serum (controls) or antibody against rat p65 diluted 
1:200. Secondary biotinylated antibody was applied next, 
and the color was developed Kit (Vector Laboratories, 
Burlingame, Calif.). The highly specific polyclonal antibody 
against p65 was obtained by immunizing rabbits with the rat 
p65 preparation purified as described above. 
Presence of p65 in Rat and Mouse Liver Tumors and its 
Absence from Normal Mouse and Rat Liver 
When total protein samples from rat and mouse liver 
carcinomas grown in vitro were analyzed by SDS-PAGE and 
then anti-rat p65 antibody probing of Western blots, a single, 
prominent band was detected in the 65 kDa region of the 
blots. Some weak bands seen in the 60-64 kDa region may 
represent degradation products of the native species of p65. 
Other minor bands resulted from non-specific Staining. 
There is no band characteristic of p65 in immunoblots 
representing normal adult rat or mouse liver. 
All hepatocarcinoma cells grown in vitro as cell cultures 
and tumor tissues from Morris hepatomas carried as Solid 
tumors in vivo were positive for the p65 antigen. There was 
no reaction with normal liver cells of either rat or mouse 
origin. Thus, immunoblotting analysis has demonstrated that 
p65 was specifically produced by liver cancer cells but not 
by the cells of normal adult rat or mouse liver. 
EXAMPLE III 
Interspecies croSS-reactivity of Antibodies Against p65 
The p65 tumor-associated factors derived from different 
Species are immunologically croSS-reactive. 
TABLE 1. 
Immunoprecipitation of p85 from Different Sources by Antibodies 
Raised in Rabbits against Rat p05. 
Source of p85 Immunoprecipitation of p85 
Plasma: 
Morris Hepatoma 7777-bearing Rats ------ 




Immunoprecipitation of p85 from Different Sources by Antibodies 
Raised in Rabbits against Rat pos. 




Morris Hepatoma 7777 Tumors ------ 
Morris Hepatoma 8994 Tumors ------ 
Normal Rat Liver 
Conditioned Culture Medium: 
Morris Hepatoma 7777 Cells ------ 
Morris Hepatoma 8994 Cells ------ 
Rat THC 1682 Cells ------ 
Mouse Squamous Cell Carcinoma ---- 
Human Breast Cancer Cells (MCF-7) ---- 
Unconditioned Culture Medium 
*+++ = Over 90% precipitation; ++ = 50-90% precipitation 
- = less than 25% precipitation 
The p65 activity as measured by the mRNA-transport 
assay was immunoprecipitated using polyclonal anti-rat p65 
antibodies from the Serum of rabbits immunized against the 
rat transplantable hepatocellular carcinoma THC 1682. This 
antibody removed activity from cytosols derived from Mor 
ris Hepatomas 7777 and 8994 and from cell culture media in 
which tumor cells were grown. Polyclonal anti-rat p65 
antibodies reacted with human p65 secreted to the culture 
medium by the MCF-7 breast cancer cell line. The anti 
bodies also cross-reacted with the mouse p65 factor secreted 
to medium by mouse Squamous cell carcinoma. The p65 
tumor-associated factor was not detected in the blood of 
pregnant rats. It was neither detected in the blood of normal 
rats nor in unconditioned cell culture medium. 
EXAMPLE IV 
CNBR Cleavage of p65 
Cyanogen bromide (CNBR) cleavage maps of p65 puri 
fied from cell culture medium of rat transplantable hepato 
cellular carcinoma cell line 1682C or mouse liver carcinoma 
cell line CRL 6421 (MM45) were obtained as follows. p65 
preparations (20) purified from cell culture medium were 
subjected to 12.5% sodium deodecyl sulfate (SDS)-PAGE. 
The p65 band located on slab gels by Coomassie blue 
Staining of parallel gel tracks was cut from appropriate gel 
tracks and incubated at room temperature for 16 hours in 1 
ml of 88% formic acid containing 20 mg/ml of CNBR. The 
gel slices were then rinsed five times with 1 ml of water and 
washed several times for 10 minutes with 1 ml 120 mM 
Tris-HCl, pH 7.0, 20% glycerol (vol/vol), 2% SOS until the 
pH of the slices reached 7.0. CNBr-treated gel slices were 
placed onto 15% SDS-PAGE slabs, electrophoresed, and 
then Stained with Silver. Slices of gel containing p65 treated 
with 88% formic acid served as controls. 
Structural Identity of Rat and Mouse p65 
Rat and mouse p65 were purified to apparent homogene 
ity as described above. CNBR cleavage maps were obtained 
as the first Step toward the final characterization of the amino 
acid composition and Sequence of p65. The cleavage of p65 
with CNBR resulted in six major peptides identifiable by 
silver staining of the SDS-PAGE gels. The peptides have 
molecular weights of about 6, 9, 270, 39, 43 and 47 kDa. 













Animal Models for Determination of Cancer Risk 
The ultimate objective of animal carcinogenicity Studies 
is the determination of possible human risk. The available 
data Show that known human carcinogens that have been 
adequately Studied are also carcinogenic in laboratory 
animals, often at the same target Site. Thus, the identification 
and elucidation of the mechanisms underlying each Stage of 
the carcinogenic process in animals may offer testable 
hypothesis for the Stages in human. The current tests for 
cancer risk assessment focus mainly on markers of genetic 
damage, at the level of the DNA or chromosome, as indi 
cators of genotoxic exposure. These tests, however, are not 
able to detect the risk associated with exposure to Synthetic 
Steroid hormones and other tumor promoters. 
It was recently indicated that the promotional Status of 
human Subpopulations could be the dominant factor in 
determining the cancer risk. The development of a more 
Systematic analysis of possible tumorigenesis mechanism 
has also been Suggested. One of the approaches to Study in 
a more Systematic way the mechanism of tumorigenesis, 
involves comparisons among different Systems in which 
tumor induction, or cell transformation has been optimized 
through the use of the most effective System-specific agents 
and protocols. When each tumor System is operating 
optimally, interSystem comparisons could be undertaken 
with respect to carefully Selected biochemical parameters. 
Tumor-associated proteins, Such as the one described herein 
which appears to be a general marker of preneoplastic and 
neoplastic alterations, are good candidates to be used in 
interSystem comparisons. 
Monitoring Skin Carcinogenesis with p65 Tumor 
ASSociated Factor 
A multistage skin carcinogenesis model was used to 
monitor the carcinogenic proceSS using the p65 tumor 
asSociated marker. 
Skin tumors were induced on the back of SENCAR mice 
by a single dose of 10 nmol of 7,12-dimethylbenza 
anthracene (DMBA) and repetitive applications of 1 lug of 
12-0-tetradecanoylphorbol-13-acetate (TPA) twice a week. 
Blood samples were randomly obtained from four mice at 
times indicated in FIG.1. The p65 activity was measured in 
the blood plasma by use of an ELISA assay. 
In a modified ELISA inhibition procedure, 100 ul of 
purified antigen of predetermined dilution was added to 
Dynatech Immunon 2 plates and incubated at 37 C. for one 
hour. This was followed by washing, then binding 1% 
bovine serum albumin in bicarbonate buffer to cover 
residual binding sites in the Wells. After Washing the plates, 
100 ul of antiserum plus test Samples were added and the 
incubation carried out for one hour at 37 C. Finally, the 
immune complex was detected by adding 100 ul of goat/ 
anti-rabbit immunoglobulin conjugated to horseradish per 
oxidase. Then the substrate 2.21-AZino-(3-ethyl- benzthia 
Zolinesulfonic acid) and 0.03% H 202 was added to each 
well and incubated 10 minutes at room temperature. After 
terminating the reaction with addition of 20 ml of 2.0 mM 
NaN3 to each well, the absorbance (405 nm) was read on an 
ELISA reader. 
For convenience of graphing, the inhibition values were 
changed to units where the Sample giving the greatest 
inhibition will be selected as the end point. The percent 
inhibition=100-(Absorbance inhibited/absorbance 
uninhibited)x100). The percent inhibition of the sample was 




Shown in FIG. 1 was the time-course of (A) papilloma 
appearance and (B) p65 accumulation in the blood plasma. 
p65 was detected in the plasma at four weeks of promotion, 
then its activity increased, first Slowly up to 20 weeks, and 
then more rapidly up to 30 weeks, when it began to plateau. 
p65 was not detected in the blood of non-initiated mice 
treated with TPA as described above up to 20 weeks (data 
not shown). 
By using a simple blood test for the presence of p65 
factor, the Skin cancer risk from the tumor promoter TPA can 
be detected as early as four weeks of treatment with the 
tumor promoter. A majority of skin papillomas are consid 
ered to be non- malignant tumors at early Stages of devel 
opment. Conventional histological and cytogenetic tech 
niques are time consuming and are able to detect skin 
cancers in mice only at later Stages of papilloma 
development, i.e., at 30-40 weeks. 
EXAMPLE VI 
Monitoring Liver Carcinogenesis with p65 Tumor 
ASSociated Factor 
Altered hepatic foci (AHF) were induced in the course of 
2-acetylaminofluorene (AAF)-initiated, phenobarbital (PB) 
-promoted hepatocarcinogenesis in the rat. Rats (male wean 
ling albinos, Sprague Dawley Strain) were purchased from 
Harlan Labs, Indianapolis, Ind. The 0.06% (w/w) AAF diet 
and 0.05% PB diet were prepared and pelleted by Altromin, 
Lage, FRG, and Dyets, Inc., Bethlehem, Pa., respectively. 
Each of two experimental groups of rats and a control group 
consisted of 40 rats. All rats entered the experiment at 22 
days of age. One group received AAF diet for 18 days, then 
AIN-76A diet (Dyets, Inc.) The second group received AAF 
diet for 18 days then AIN-76A diet for 24 days and then 
AIN-76A diet Supplemented with 0.05% phenobarbital. The 
third group (controls) received AIN-76A diet for 42 days, 
then AIN- 76A diet plus 0.05% phenobarbital. 
Immunohistochemical Procedures 
The blood and livers of rats (4 animals per each time 
point) Sacrificed at different times in the course of hepato 
carcinogenesis experiment were used for immunochemical 
Studies. Paraffin liver Sections were prepared and Stained 
with specific antibodies. Polyclonal antibodies to the rat p65, 
purified to apparent homogeneity, were raised in rabbits as 
described herein. The p65 was visualized in the liver sec 
tions using the avidin- biotin-peroxidase complex 
(Vectastain ABC Kit, Vector Laboratories, Burlingame, 
Calif.). Appropriate controls with non-immune serum were 
performed routinely. Antiserum to p65 was diluted 1:200 in 
PBS with 1% goat serum for use in the staining protocol. 
The blood plasma was assayed for the presence of p65 using 









The p65 tumor-associated protein was detected in rats fed 
AAF and PB diets as early as two weeks of feeding with the 
tumor promoter PB. The p65 marker was predominantly 
present in the cells of putative preneoplastic foci found at 24 
weeks of trial in livers of rats fed AAF and PB diets. The p65 
marker was highly concentrated in the foci with little or none 
being detected in the Surrounding cells. Either no Staining or 
weak positive Staining was found in the areas known for Oval 
and ductular proliferation. No positive Staining was found in 
control livers from normal rats or rats fed only the PB diet. 
Most of p65 activity appears to be associated with the nuclei 
of the p65-positive hepatocytes and more precisely with the 
nuclear envelopes, with relatively little being detected in the 
cytoplasm. Immunohistochemical Staining of the croSS 
Sectioned nuclei revealed that only the periphery of the 
nuclei, i.e., nuclear envelopes, were Stained. 
EXAMPLE VII 
Enhancement of p65 Production During Sex Hormone 
Promotion 
Shown in FIG. 2 is the effect of the contraceptive steroid 
ethynylestradiol (EE), a known tumor promoter in the rat, on 
the p65 production in female rats initiated with N-methyl 
nitroSourea (MNU), using a protocol designed to induce 
mammary gland tumors. 
A short (one week) exposure to EE at Six to Seven weeks 
post-carcinogen treatment, i.e., when the MNU-induced 
production of p65 was relatively low, caused three-fold 
increase of the p65 level in the blood plasma. MNU was 
shown to induce pre-neoplastic foci in the liver; however, 
they were not detected by the use of the gamma-glutamyl 
transpeptidase (GGT) assay, even after 23-week promotion 
with EE. Thus the 65 production in the rat appears to be 
extremely Sensitive to hormonal Stimulation. The high Sen 
Sitivity of the p65 Synthesis during chemical carcinogenesis 
to SeX and phenobarbital promotion indicate that p65 can be 
used not only as a tumor marker, but also for early assess 
ment of cancer risk associated with the use of Synthetic 
Steroids and other drugs that exhibit tumor promotion prop 
erties. 
Evidence of resemblance of p65 to Steroid Receptors 
p65 amino acid sequence (SEQ ID NO: 2) deduced from 
the cDNA sequence. Blocks of Zinc figure Structures are 
underlined and SV40 translocation domain is double under 
lined. Fragments of the Sequence in bold are peptide 
sequences obtained from the purified protein after CNBr 
cleavage. 
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301 MAS LAL D S R G KAA GPRR GAR R L C L V C E D YA 
351 O GNT D YY C F T N D C NI SKN R S K S CP A C L L R C 
401 NW GE E V DMT G P S WT CLK LLF SD GE KV P R L. 
451 S P P KKR K G W P P G HVLS ND R AAA GT W WKP K 
5O1 TF W L G S RANK AL G. KG G T R G R YI KHP EHL FK 
Additional evidence that p65 may indeed belong to a 
Superfamily of Steroid receptors comes from the cloning and 
sequencing of rat p65 cINA. The C-terminal end of p65 
cDNA contains two Sequences homologous to Zinc fingers. 
Specifically, the Sequence of the Cl region of p65 is very 
similar to several other steroid hormones. FIG. 3 depicts a 
proposed Zinc finger Structure of p65. 
Post-translational modification of receptorS is a possible 
mechanism by which receptor function can be regulated. 
Glucocorticoid, progesterone, estrogen and Vitamin D recep 
tors as well as p65 are phosphoproteins. The 
phosphorylation/dephosphorylation proceSS is most likely a 
control mechanism for the regulation of transformation, 
hormone binding, DNA binding and transactivation. In 
addition, a prenylation site was found not very far from the 
C-terminal end. This is also post-translational modification 
by the attachment of either a farnesyl or geranyl/geranyl 
group to cysteine residues located at C-terminal extremity. 
Such modification is characteristic for Several Ras and 
Ras-like proteins and nuclear lamins A and B as well as a 
number of G-proteins (transducins). 
The intracellular localization of Steroid receptors after 
Synthesis has been Studied extensively and it is proposed that 
cytoplasmic receptorS bind hormone and rapidly translocate 
to the nucleus. This fact may explain immunostainings 
showing the presence of p65 not only in nuclei, but also in 
the cytoplasm in breast cancer tissues. Nuclear localization 
of proteins may occur by two different mechanisms. One is 
the diffusion of proteins through nuclear membrane; Second, 
an interaction of proteins with the nuclear pores. This 
proceSS is mediated by a translocation Signal in the protein. 
Amino acid Sequences having Strong homology to the 
nuclear translocation signal of SV 40 T antigen have been 
found in Several Steroid receptors. The Sequence above 
shows comparisons of highly homologous domains of trans 
location Signal from human Steroid receptors like GR, MR, 
AR, PR, ER and p65. These sequences, in the case of p65, 
are located close to the C-terminal site of the DNA-binding 
domain (Cl region), Similarly to other receptor proteins in 
this family. It is still unknown, but is being actively Studied, 
as to what Serves as a ligand for p65. 
The following examples describe in detail the protocols 
utilized to identify and Sequence the p65 gene as well as to 
make hybridization probes for the identification of p65 
protein in a Sample. 
EXAMPLE VIII 
Cloning and Sequencing of the p65 gene 
An H-35 Reuber hepatoma rat cDNA library was screened 
using rat anti-p65 monoclonal antibodies and have found to 
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p65, having approximately 1200 bp. Several hundred nucle 
otides (reverse and forward) from both sides of this clDNA 
was Sequenced. po5 cDNA was cloned in plasmid 
pTA65Hum and used to transform E. coli JM 105 strains. 
Single-Stranded templates were prepared and Sequenced by 
the dideoxy chain-termination procedure (Messing J., Meth 
ods in Enzymology, 101: 20–78, 1983). The sequencing 
reaction was primed with either the universal primerS or 
Specific oligonucleotides complementary to Sequence 
already determined (Strauss, E. C. et al., Anal. Biochem. 
154: 353–360, 1986). The DNA sequences were analyzed 
with the GCG DNA Sequence Analysis Program. Initially, 
an 800-900 bp sequence data for the C-terminal end of the 
rat p65 cDNA (open reading frame) was obtained. Two 
polyadenylation signals (TTTAATT in p65 clDNA or AAAT 
TAA in mRNA) and the poly A tail containing 18 As were 
found. Next, in the 1200 bp p65 cDNA fragment of p65 two 
fragments homologous to oligonucleotides backtranslated 
from the amino acid Sequence of the p39 and p51 peptides 
of p65 were found. This was a strong confirmation that the 
proper cDNA fragment of p65 had been isolated. The 
nucleotide Sequences were next assembled and analyzed 
with Gene Jockey and DNA Strider softwares (Biosoft, 
Cambridge, UK). The Sequence similarities were searched 
by GCG package through GeneBank and Owl data bases. 
Hybrid p65-like proteins encoded by recombinant clones 
were induced with IPTG. Lysates were prepared and ana 
lyzed by SDS-PAGE gel electrophoresis and Western blot 
assay. The anti-p65 MAbs revealed immunoreactivity with 
respective B-galactosidase/p65 fusion proteins, as indicated 
by immunoblot analysis on bacterial cell extracts. MAbs 
were unreactive with other antigens present in different 
bacterial lysates and with B-galactosidase alone in p3lue 
script plasmid. The p65-like bacterial product was found to 
have molecular mass of 36 kDa as determined by 
Coomassie-blue-stained SDS-PAGE gel. These findings 
supported the theory that this cDNA clone coded for a 
fragment of the desired antigen. 
It should be emphasized that the p65-like products, 
reacted identically with both monoclonal and polyclonal 
anti-p65 antibodies in immunoblotting experiments. 
Sequencing efforts were continued in order to obtain the 
full sequence of the 1200 bp cDNA fragment. Because p65 
has a molecular weight 65 kDa, the expected length of the 
clone containing rat p65 cDNA was estimated to be approxi 
mately 2000 bp. AS discussed above, initial Screening 
attempts, using monoclonal antibodies, to obtain the full 
cDNA sequence were not Successful. Specifically, only 
fragments of the p65 gene with the C-terminal end or close 
to the C-terminal end were determinable. The N-terminal 
end (approximately 800 bp) was always missing. Therefore, 
a RACE PCR protocol was used to obtain the missing 
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Sequences. This protocol eventually resulted in the determi 
nation of the full cl)NA sequence of rat p65 shown in SEQ 
ID NO: 1. The p65 amino acid sequence deduced from the 
cDNA sequence is shown in SEQ ID NO: 2. 
PCR amplification of 5'-end p65 cDNA 
5' AmpliFINDER anchor primer (CLONTECH 
Laboratories, Inc.) and Specific to p65 cDNA antisense 
primer 5"CAGGTCCAGCTAGGACCGGG3' was used for 
amplification of the 5' end of p65 cDNA. Maximum ampli 
fication specificity was obtained using “hot start PCR 
(D'Aquila, R. T., Nucleic Acids Res. 19:3749, 1991). PCR 
reactions were carried out as described (Sambrook J. et al., 
Molecular Cloning : A Laboratory Manual, Cold Spring 
Harbor Laboratory, Cold Spring Harbor, N.Y., 1989). Ampli 
fication product was analyzed by agarose electrophoresis 
and Southern hybridization. Selected PCR product was 
purified from the acrylamide gel and cloned into TA vector, 
using TA cloning kit from Invitrogen Co. p65 inserts after 
EcoRI digestion recombined TAH10 plasmid were recloned 
into Bluscript II KS at EcoRI site. 
Southern blot analysis 
Amplification products were fractionated by electro 
phoresis in 1% agarose gel containing 1XTAE buffer (40 
mM Tris-HCl, 18 mM NaCl, 20 mM sodium acetate, and 2 
mM EDTA) after alkaline denaturation (Freeman M. R., 
Cancer Res., 49: 6221-6225, 1989). DNA was transferred 
from agarose gel to nitrocellulose (Schleicher & Schuell) 
according to Southern (Southern, E. M., J. Mol. Biol., 98 : 
503–518, 1975). The membrane was baked for 2 hat 80° C. 
and prehybridized in a hybridization buffer (5xSSC, 
5xDenhardt’s solution, 10% dextran sulfate, 1% SDS, 20 
ug/ml of salmon sperm DNA in 50% formamide) in 42°C., 
then hybridized with “P-random primed cDNA probe 
overnight at the same temperature. After hybridization, the 
membrane was washed in 2xSSC at room temperature for 30 
min. and then the membrane was washed under high Strin 
gency conditions (0.5xSSC, 1% SDS) at 65° C. for 15 min. 
Autoradiography was performed using Hyperfilm TM-MP 
from Amersham with the intensifying screen at -80 C. 
Expression of the p65 Gene in Recombinant Vectors 
After identifying and isolating the p65 DNA molecule, it 
may be inserted into any one of the many vectors currently 
known in the art and transferred to a prokaryotic or eukary 
otic host cell where it will direct the expression and pro 
duction of the So-called recombinant version of the protein. 
A technique often employed by those skilled in the art of 
protein production today is to obtain a So-called “recombi 
nant version of the protein, to express it in a recombinant 
cell and to obtain the protein from such cells. To achieve 
this, a Specific oligonucleotide based upon the Sequence of 
the desired peptide, as is known to those of Skill in the art 
and described herein is prepared. The oligonucleotide is then 
inserted into an expression vector, Such as any one of the 
many expression vectors currently available commercially. 
A prokaryotic or eukaryotic host cell is then transformed 
with the vector, where it will direct the expression of the 
So-called recombinant version of the peptide, which may 
then be purified from the recombinant host cell. The prepa 
ration of oligonucleotide, Vector and transformation of the 
host cell are within the skill of the ordinary artisan and is 
described in detail in Sambrook et al. (1989). 
Particularly useful vectors are contemplated to be those 
vectors in which the coding portion of the DNA segment, 
whether encoding a full length protein or Smaller peptide, is 
positioned under the control of a promoter. The promoter 











asSociated with a p65 gene, e.g., in p65 tumor associated 
cells, as may be obtained by isolating the 5' non-coding 
Sequences located upstream of the coding Segment or exon, 
for example, using recombinant cloning and/or PCR 
technology, in connection with the compositions disclosed 
herein. 
In other embodiments, it is contemplated that certain 
advantages will be gained by positioning the coding DNA 
Segment under the control of a recombinant, or 
heterologous, promoter. AS used herein, a recombinant or 
heterologous promoter is intended to refer to a promoter that 
is not normally associated with a rat p65 tumor marker gene 
in its natural environment. Naturally, it will be important to 
employ a promoter that effectively directs the expression of 
the DNA segment in the cell type chosen for expression. The 
use of promoter and cell type combinations for protein 
expression is generally known to those of skill in the art of 
molecular biology, for example, see Sambrook et al. (1989). 
The promoters employed may be constitutive, or inducible, 
and can be used under the appropriate conditions to direct 
high level expression of the introduced DNA segment, Such 
as is advantageous in the large-scale production of recom 
binant proteins or peptides. 
AS mentioned above, in connection with expression 
embodiments to prepare recombinant rat p65 proteins and 
peptides, it is contemplated that longer DNA segments will 
most often be used, with DNA segments encoding the entire 
p65 protein being most preferred. However, it will be 
appreciated that the use of Shorter DNA segments to direct 
the expression of shorter peptides or epitopic core regions, 
Such as may be used to generate antibodies, also falls within 
the scope of the invention. Single stranded DNA molecules 
coding for the p65 protein can then be created and Subse 
quently Sequenced by the dideoxy chain termination proce 
dure as described in Messing (1983). In addition, fragments 
may be expanded through the use of PCR technology of U.S. 
Pat. No. 4,603,102 (incorporated herein by reference). 
Nucleic Acid Sequence of the p65 Molecule 
Important aspects of the present invention concern iso 
lated DNA segments and recombinant vectors encoding the 
65 kDa oncofetal protein, and the creation and use of 
recombinant host cells through the application of DNA 
technology, that express this 65 kDa tumor marker protein. 
As used herein, the term “DNA segment” refers to a DNA 
molecule that has been isolated free of total genomic DNA 
of a particular species. Therefore, a DNA segment encoding 
the rat p65 oncofetal protein refers to a DNA segment that 
contains p65 coding Sequences yet is isolated away from, or 
purified free from, total genomic DNA of the rat. Included 
within the term “DNA segment', are DNA segments and 
Smaller fragments of Such Segments, and also recombinant 
Vectors, including, for example, plasmids, cosmids, phage, 
Viruses, and the like. 
Similarly, a DNA segment comprising an isolated or 
purified rat p65 gene refers to a DNA segment including p65 
coding Sequences and, in certain aspects, regulatory 
Sequences, isolated Substantially away from other naturally 
occurring genes or protein encoding Sequences. In this 
respect, the term “gene' is used for Simplicity to refer to a 
functional protein, polypeptide or peptide encoding unit. AS 
will be understood by those in the art, this functional term 
includes both genomic Sequences, cDNA sequences and 
Smaller engineered gene Segments that express, or may be 
adapted to express proteins, polypeptides or peptides. 
Isolated Substantially away from other coding Sequences' 
means that the gene of interest, in this case p65, forms the 
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Significant part of the coding region of the DNA segment, 
and that the DNA segment does not contain large portions of 
naturally-occurring coding DNA, Such as large chromo 
Somal fragments or other functional genes or cDNA coding 
regions. Of course, this refers to the DNA segment as 
originally isolated, and does not exclude genes or coding 
regions later added to the Segment by the hand of man. 
In preferred embodiments, the invention concerns isolated 
DNA segments and recombinant vectors incorporating DNA 
Sequences that encode the rat p65 oncofetal protein com 
prising a sequence region having the Sequence of SEQ ID 
NO: 1 
The term “comprising a sequence region having the 
sequence of SEQ ID NO: 1” means that the sequence 
substantially corresponds to a portion of SEQ ID NO: 1 and 
has relatively few amino acids that are not identical to the 
amino acids of SEQ ID NO: 1. Accordingly, sequences that 
have between about 70% and about 80%; or more 
preferably, between about 81% and about 90%; or even 
more preferably, between about 91% and about 99%; of 
amino acids that are identical or functionally equivalent to 
the amino acids of SEQ ID NO: 1 will be sequences that 
“comprising a sequence region having the Sequence of SEQ 
ID NO: 1. The most preferred embodiment of the present 
invention consists of a protein molecule of SEQ ID NO: 1. 
Naturally, where the DNA segment or vector encodes a 
full length p65 protein, or is intended for use in expressing 
the p65 protein, the most preferred Sequences are those that 
are essentially as set forth in SEQ ID NO: 1 and that encode 
a protein that retains immunologic activity, e.g., as may be 
determined by the antibody assay, as disclosed herein. 
Sequences Complementary to the p65 Molecule 
Naturally, the present invention also encompasses DNA 
and RNA segments that are complementary, or essentially 
complementary, to the sequence set forth in SEQ ID NO: 1. 
Nucleic acid Sequences that are “complementary are those 
that are capable of base-pairing according to the Standard 
Watson-Crick complementarity rules. AS used herein, the 
term “complementary Sequences' means nucleic acid 
Sequences that are Substantially complementary, as may be 
assessed by the same nucleotide comparison Set forth above, 
or as defined as being capable of hybridizing to the nucleic 
acid segment of SEQ ID NO: 1 under relatively stringent 
conditions Such as those described herein in Example 10. 
Amino Acid Sequence of the p65 Protein Molecule 
In certain other embodiments, the invention concerns the 
rat p65 protein having the sequence of SEQ ID NO: 2. The 
term “having the sequence of SEQ ID NO: 2 is used in the 
Same Sense as described above and means that the nucleic 
acid Sequence Substantially corresponds to a portion of SEQ 
ID NO: 2 and has relatively few codons that are not 
identical, or functionally equivalent, to the codons of SEQ 
ID NO: 2. The term “functionally equivalent codon” is used 
herein to refer to codons that encode the same amino acid, 
Such as the six codons for arginine or Serine, and also refers 
to codons that encode biologically equivalent amino acids. 
The term “functionally equivalent codon” is well understood 
in the art. 
Certain amino acids can be Substituted for other amino 
acids in a Sequence without appreciable loSS of immunologic 
activity. 
In making Such changes, the hydropathic index of amino 
acids can be considered. The importance of the hydropathic 
amino acid indeX in conferring interactive biologic function 
on a peptide is generally understood in the art (Kyte & 











certain amino acids can be Substituted for other amino acids 
having a similar hydropathic indeX or Score and Still result 
in a peptide with Similar biological activity. Each amino acid 
has been assigned a hydropathic indeX on the basis of its 
hydrophobicity and charge characteristics. Those indices 
are: isoleucine (+4.5); Valine (+4.2); leucine (+3.8); pheny 
lalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); 
alanine (+1.8); glycine (-0.4); threonine (-0.7); Serine 
(-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); 
histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspar 
tate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine 
(-4.5). 
It is understood in the art that the relative hydropathic 
character of the amino acid determines the Secondary Struc 
ture of the resultant peptide, which in turn defines the 
interaction of the peptide with other molecules, Such as 
enzymes, Substrates, receptors, antibodies, antigens, and the 
like. It is known in the art that an amino acid can be 
Substituted by another amino acid having a Similar hydro 
pathic indeX and Still obtain a functionally equivalent pep 
tide. In Such changes, the Substitution of amino acids whose 
hydropathic indices are within t2 is preferred, those which 
are within t1 are particularly preferred, and those within 
+0.5 are even more particularly preferred. 
Substitution of like amino acids can also be made on the 
basis of hydrophilicity, particularly where the biological 
functional equivalent peptide thereby created is intended for 
use in immunological embodiments. U.S. Pat. No. 4,554, 
101, incorporated herein by reference, States that the greatest 
local average hydrophilicity of a peptide, as governed by the 
hydrophilicity of its adjacent amino acids, correlates with its 
immunogenicity and antigenicity, i.e. with a biological prop 
erty of the peptide. 
As detailed in U.S. Patent 4,554,101, the following hydro 
philicity values have been assigned to amino acid residues: 
arginine (+3.0); lysine (+3.0); aspartate (+3.0+1); glutamate 
(+3.0t1); Serine (+0.3); asparagine (+0.2); glutamine (+0.2); 
glycine (O), proline (-0.5-1); threonine (-0.4); alanine 
(-0.5); histidine (-0.5); cysteine (-1,0); methionine (-1.3); 
valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine 
(-2.3), phenylalanine (-2.5); tryptophan (-3.4). It is under 
stood that an amino acid can be Substituted for another 
having a similar hydrophilicity value and Still obtain a 
biologically equivalent, and in particular, an immunologi 
cally equivalent peptide. In Such changes, the Substitution of 
amino acids whose hydrophilicity values are within t2 is 
preferred, those which are within t1 are particularly 
preferred, and those within t0.5 are even more particularly 
preferred. 
AS outlined above, amino acid Substitutions are generally 
therefore based on the relative similarity of the amino acid 
Side-chain Substituents, for example, their hydrophobicity, 
hydrophilicity, charge, size, and the like. Exemplary Substi 
tutions which take various of the foregoing characteristics 
into consideration are well known to those of skill in the art 
and include: arginine and lysine; glutamate and aspartate; 
Serine and threonine; glutamine and asparagine; and Valine, 
leucine and isoleucine (See table below). The present inven 
tion thus contemplates functional or biological equivalents 
of a peptide inhibitor of plasminogen activator inhibitor-1 as 
set forth above. 
It will also be understood that amino acid and nucleic acid 
Sequences may include additional residues, Such as addi 
tional N- or C-terminal amino acids or 5' or 3' Sequences, 
and yet Still be essentially as Set forth in one of the Sequences 
disclosed herein, So long as the Sequence meets the criteria 
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Set forth above, including the maintenance of biological 
protein activity where protein expression is concerned. The 
addition of terminal Sequences particularly applies to nucleic 
acid Sequences that may, for example, include various 
non-coding Sequences flanking either of the 5' or 3' portions 
of the coding region or may include various internal 
Sequences, i.e., introns, which are known to occur within 
geneS. 
The following examples are given by way of illustration, 
without intent to limit the scope of the invention, to show 
details of particularly preferred reagents and techniques 
utilized in the processes of the instant invention. 
EXAMPLE IX 
Creation of Hybridization Probes 
Another important aspect of this invention resulting from 
the Sequencing of the p65 protein is the ability to make and 
use hybridization probes for use in the detection of cancer. 
The use of a hybridization probe of about 10-14 nucle 
otides in length allows the formation of a duplex molecule 
that is both stable and selective. One might also prefer to 
design nucleic acid molecules having gene-complementary 
Stretches of 15 to 20 contiguous nucleotides, or even longer 
where desired. 
Hybridization probes may be selected from any portion of 
any of the Sequences disclosed herein. All that is required is 
to review the sequence set forth in SEQ ID NO: 1 and to 
Select any continuous portion of the Sequence, from about 
10-14 nucleotides in length up to and including the full 
length Sequence, that one wishes to utilize as a probe or 
primer. The choice of probe and primer Sequences may be 
governed by various factors, Such as, by way of example 
only, one may wish to employ primers from towards the 
termini of the total Sequence, or from the ends of the 
functional domain-encoding Sequences, in order to amplify 
further DNA, one may also employ probes corresponding to 
regions of the entire DNA that are homologous to genes 
from any Species including human in order to Screen for 
CCC. 
Accordingly, the nucleotide Sequences of the invention 
may be used for their ability to selectively form duplex 
molecules with complementary Stretches of p65 genes or 
cDNAS. Depending on the application envisioned, one will 
desire to employ varying conditions of hybridization to 
achieve varying degrees of Selectivity of probe towards 
target Sequence. For applications requiring high Selectivity, 
one will typically desire to employ relatively Stringent 
conditions to form the hybrids, e.g., one will Select relatively 
low Salt and/or high temperature conditions, Such as pro 
vided by 0.02M-0.15M NaCl at temperatures of 50° C. to 
70° C. Such selective conditions tolerate little, if any, 
mismatch between the probe and the template or target 
Strand, and would be particularly Suitable for isolating rat 
p65 genes. 
In certain embodiments, it will be advantageous to 
employ nucleic acid Sequences of the present invention in 
combination with an appropriate means, Such as a label, for 
determining hybridization. A wide variety of appropriate 
indicator means are known in the art, including fluorescent, 
radioactive, enzymatic or other ligands, Such as avidin/ 
biotin, which are capable of giving a detectable signal. In 
preferred embodiments, one will likely desire to employ a 
fluorescent label or an enzyme tag, Such as urease, alkaline 
phosphatase or peroxidase, instead of radioactive or other 
environmental undesirable reagents. In the case of enzyme 











employed to provide a means visible to the human eye or 
Spectrophotometrically, to identify Specific hybridization 
with complementary nucleic acid-containing Samples. 
In general, it is envisioned that the hybridization probes 
described herein will be useful both as reagents in solution 
hybridization as well as in embodiments employing a Solid 
phase. In embodiments involving a Solid phase, the test 
DNA (or RNA) is adsorbed or otherwise affixed to a selected 
matrix or Surface. This fixed, single-Stranded nucleic acid is 
then subjected to specific hybridization with selected probes 
under desired conditions. The selected conditions will 
depend on the particular circumstances based on the par 
ticular criteria required (depending, for example, on the 
G+C contents, type of target nucleic acid, Source of nucleic 
acid, size of hybridization probe, etc.). Following washing 
of the hybridized Surface So as to remove nonspecifically 
bound probe molecules, specific hybridization is detected, or 
even quantified, by means of the label. 
p65 mRNA-specific oligonucleotide probes may be used 
for detecting proliferating cells like cancerous cells in tissue/ 
cell Samples. The steps include (a) preparation of tissue/cell 
Sample; (b) hybridization with cocktail of non-radioactively, 
or radioactively labeled oligonucleotide probes for p65 
mRNA; and (c) detecting the presence of p65 probe hybrids. 
EXAMPLE X 
AntiSense Technology 
Inhibition of gene function with antisense nucleotides 
may have Some therapeutic utility. Therefore, Series of 
antisense phosphorothioate oligonucleotides complemen 
tary to the p65 nucleotide Sequence were prepared that can 
be used to inhibit expression of the p65 gene in breast, ovary 
and prostate cancer cell lines, as well as other cancer cell 
lines. The oligonucleotides are effective only when com 
plexed with Lipofectin and the level of expression may be 
reduced by approximately 50-80%. In experiments with the 
antisense expression the Steady-state level of mRNA is 
reduced. AntiSense therapy using Small oligonucleotide anti 
sense molecules of p65 mRNA or DNA as well as or 
defective retrovirus or adenovirus carrying the antisense 
ribo- or deoxy-Sequences of p65, respectively, may be very 
effective in the prevention and or treatment of cancer. 
REFERENCES CITED 
1. Mirowski, M., Sherman, U., and Hanausek, M. Puri 
fication and characterization of a 65-kDa tumor 
asSociated phosphoprotein from rat transplantable 
hepatocellular carcinoma 16820cell line. Protein 
Expression and Purification, 3:196-203, 1992. 
2. Wang, S., Mirowski, M., Sherman, U., Walaszek, Z., 
and Hanausek, M. Monoclonal antibodies against a 65 
kDa tumor-associated phosphoprotein: development 
and use in cancer detection. Hybridoma, 12:167-176, 
1993. 
3. Mirowski, M., Walaszek, Z., Sherman, U., Adams, A. 
K. and Hanausek, M. Demonstration of a 65 kDa 
tumor-specific phosphoprotein in urine and Serum of 
rats with N-methyl-N-nitrosourea-induced mammary 
adenocarcinoma. Carcinogenesis 14:8, 1659-1664, 
1993. 
4. Mirowski, M., Walaszek, Z., Sherman, U., Adams, A. 
K. and Hanausek, M. Comparative Structural analysis 
of human and rat 65 kDa phosphoprotein. Int. J. 
Biochem, 25:1865-1871, 1993. 
5. Del Rio, M., Hanausek M., Walaszek, Z. and Stoica, G. 
Expression of a 65 kDa oncofetal phosphoprotein in the 
altered hepatic foci of rats fed 2-acetylaminofluorene 
followed by phenobarbital. Int. J. Oncology 5:259-265, 
1994. 
6. Mirowski, M., Klijanienko, J., Wang, S., Vielh, P., 
Walaszek, Z. and Hanausek, M. Serological and immu- 5 
nohistochemical detection of a 65 kDa protein breast 
21 
cancer. Eur: J. Cancer, 30A:1108-1113, 1994. 
7. Southern, E. M. Detection of Specific Sequences among 
DNA fragments Separated by gel electrophoresis. J . 
Mol. Biol., 98:503–518, 1975. 
8. Freeman M. R., Washecka, R., and Chung L. W. K. 
Aberrant expression of epidermal growth factor recep 
( 1) GENERAL INFORMATION: 
( i i i ) NUMBER OF SEQUENCES: 2 
( 2) INFORMATION FOR SEQ ID NO:1: 
5,773,215 
22 
tor and Her-2 (erbB-2) messenger RNAS in human 
renal cancers. Cancer Res., 49:6221-6225, 1989. 
9. Strauss, E. C. et al., Use of the universal primers or 
Specific oligonucleotides complementary to Sequences 
already determined. Anal. Biochem. 154:353–360, 
1986. 
10. Messing J. A System for Shotgun DNA sequencing. 
Methods in Enzymology, 101:20-78, 1983. 
11. Sambrook J. et al., Molecular Cloning: A Laboratory 
Manual,Cold Spring Harbor Laboratory, Cold Spring 
SEQUENCE LISTING 
( i) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 2070 base pairs 
(B) TYPE: nucleic acid 
( C ) STRANDEDNESS: single 
(D) TOPOLOGY: linear 
( i i ) MOLECULETYPE: DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:1: 
GA C C C C G A GA 
G CT AGA CAGA 
C T G A G G C T G G 
T C C C T C C GC G 
G C T C T G G G T G 
G T G GAG GA CA 
GAG G T G T ATG 
GC GAAAG G GA 
G T G G CT AAAA 
CA C G C C CATT 
GAG G G T G G CA 
GA T GAA GAT C 
G CCAA CA CTT 
T C C G A CGA GA 
AAT A T G A C CA 
G CAT C C C T C G 
C T G T G C C T G G 
GCC TA CAAG G 
GATT G CAA CA 
CA C C CTA G CA 
GT T G G T GAA G 
GA T G GAGAAA 
A C G T G A GAGC 
GAC T G C G AT G 
T C GATT G GAT 
G G T A C C T C GA 
G G GATAC CAG 
C C C TT GT CAA 
G T G AT GAC GT 
CATT CAGAGA 
AAG CCTT GT C 
A T G GC GAT GA 
AAA GAG GC GT 
TT G G CTTT C C 
G G T AAA GA CA 
ATAAAA C C TT 
CAG G T G A CAG 
C C C T G GATT C 
T G T G T G A G GA 
T CTT CTTT C G 
T C T CTA A GAA 
T CAA T G A GAT 
A G G T G GATAT 
AA GT GATAC C 
CGAGGGC GGG 
CA G CA CTA AG 
CGA G CA. GG AT 
ATT G CAC CT G 
A C C T G A C C C C 
A GA CAA G CT G 
A G G C T C T CAG 
TAAG G A CAAA 
C T C A G CAATT 
AAT C C T CTAC 
G GAGAT C CAC 
C CAAATAATT 
GG AT CT GAAA 
T G T G A GAG GA 
AAA TT CAAAA 
TAGGG G CAAA 
CTA T G C C A G C 
C C GAA GT CAG 
TAGAT CTA AG 
CCG AAAAG AC 
GA C C G GT C CT 
CAGATT G GCC 
GA CA T G A G G G 
AATA GT CTTC 
CT CAA GA G CA 
CAA T G CG G GA 
AAGAA G C C GC 
A G C C CAA GTA 
G C T G CG GA CA 
A TT GAA G C GC 
A CT T G GT T C C 
AAG GAT GAAT 
C C C C C A GATA 
G T G AT TAA CG 
TAT CATA ACA 
T G T AGAAAAG 
AAG G C C C A G C 
G C C GC GGG GC 
T G T T CAAA CA 
G GAA ACA CAG 
T CTT G C C CAG 
AA G CGA G CAG 
A G C T G GAC CT 
CAT GAA CTTC 
Harbor, N.Y., 1989. 
A GAA A G T G A G 
T C GT T G CTAG 
CT T G C GAAAA 
GAC GAAAAG A 
GGG G G G G C T C 
G C GC GGTTT G 
G C C C GAG GAA 
T G TT CAA G CT 
C CAA CAG C GT 
C C G G G CTT GT 
A CT T C G G CAT 
T GAA G CCT CA 
G T G CAAA CGA 
A T G G G CAT AG 
C C GT AAA CTT 
C C C G G C GC GG 
C CT G T G T C T G 
A CT ACTATTG 
C C T G C C T C CT 
C GCT GAA T GT 
G C C T GAA G CT 
CA. GGG AT CAA 
A CT G T C C A G C 
AAC AT G C G T G 
GGCT CAC GTT 
GGTT G C C G G G 
CAAAAAG AAC 
C GA GT C C C C C 
A CAG C T G GCC 
C GGG G A G CT G 
GT C G C C T CTA 
CAAC AT TA G C 
CA CAA C C C TT 
AA C C G A G GAA 
GGC C G G GTAC 
T G A G C G T AAC 
C T C C C T CAT G 
A G CGA. GGC GC 
GT C C T G T GAA 
TTT CA CAAA C 
T C GT T G C C T G 
GCGAGA CAA C 
A CT CTTTT CA 











53 O 5 35 5 4 O 
His H is Arg G 1 in Arg Phe Al a G 1 u Le u Le u Le u Lys I le Ser H is I le 
5 4 5 5 5 O 55 5 5 6 O 
A rig H is Me t V a 1 G 1 u G 1 y V a 1 A 1 a H is Cy s Le u Ty r A s p Me t Lys V a 1 
5 6 5 5 7 O 5 7 5 
Lys A s p Lys V a 1 Le u Pro Ser T r p Lys V a 1 G 1 u Lys Le u A rig L y s Ty r 
58 O 5 85 5 9 O 
V a 1 G 1 u Thir Le u A rig Thr G 1 u As in G 1 u H is Arg V a 1 A a G 1 u A a Sle r 
5 9 5 6 O O 6 O 5 
Pro G | n Th r Xa a A a G 1 u Cy s Pro G 1 y Le u Le u H is Le u G | n Sle r A 1 a 
6 1 O 6 1 6 2 O 
Ser G 1 in Th r Le u Ph e Pro G 1 y Pro A 1 a G 1 u A 1 a I le Me t G 1 y Me t Arg 
6 25 6 3 O 6 3 5 6 4 O 
S e r S e r T r p Le u Le u A a A a I e Lys Arg Ty r Me t S e r Xa a Ph e V a 1 
6 4.5 6 5 O 6 55 
V a 1 T h r H is Cy s A rig A 1 a Pro A rig L e u A 1 a Cy s G 1 y Ser V a 1 Ser Lys 
6 6 6 65 6 7 O 
V a 1 I le G 1 y I 1 e Arg Ser As n Xa a T h r S e r Le u Xa a Ph e Lys Lys Lys 
6 7 5 6 8 O 68 5 
Ly is Lys Ly s 
69 
What is claimed is: 30 10. A method of using a DNA segment having the 
1. A nucleic acid molecule of less than 2200 base pairs 
(DNA) or less than 2200 bases (RNA) substantially free of 
other proteinaceous and nucleic acid materials, wherein Said 
molecule is Selected from the group consisting of: 
a. a DNA segment comprising a Sequence region having 
the sequence of SEQ ID NO: 1; and 
b. an RNA segment comprising a Sequence region having 
the sequence of SEQ ID NO: 1 with a proviso that in 
said RNA molecule, the deoxynucleotides A, G, C and 
T of SEQ ID NO: 1 are replaced by ribonucleotides A, 
G, C and U, respectively. 
2. The nucleic acid molecule of claim 1 substantially free 
of other proteinaceous and nucleic acid materials, wherein 
Said molecule is Selected from the group consisting of 
a. a DNA molecule having a sequence of SEQ ID NO: 1; 
and 
b. an RNA molecule having a sequence of SEQ ID NO: 
1 with a proviso that said RNA molecule, the deox 
ynocleotides A, G, C and T of SEQ ID NO: 1 are 
replaced by ribonucleotides A, G, C and U, respec 
tively. 
3. The nucleic acid molecule of claim 1, wherein said 
molecule is a DNA segment and is under the control of a 
promoter. 
4. The nucleic acid molecule of claim 1, wherein Said 
molecule is a DNA segment and is incorporated into a DNA 
plasmid. 
5. The nucleic acid molecule of claim 1, wherein said 
molecule is a DNA segment incorporated into a host cell to 
form a recombinant host cell. 
6. The host cell of claim 5, further defined as a prokaryotic 
host cell. 
7. The host cell of claim 6, wherein the prokaryotic cell 
is E. coli. 
8. The host cell of claim 5, further defined as a eukaryotic 
host cell. 
9. A protein molecule Substantially free of other proteina 
ceous and nucleic acid materials, Said protein molecule 








sequence of SEQ ID NO: 1 comprising the steps of: 
a. preparing a recombinant vector in which the Sequence 
region having the sequence of SEQ ID NO: 1 is 
positioned under the control of a promoter, 
... introducing Said recombinant vector into a host cell to 
generate a recombinant host cell; 
... culturing the recombinant host cell under conditions 
effective to allow expression of the protein encoded by 
the Sequence region having the Sequence of SEQ ID 
NO: 1; and 
d. collecting the protein encoded by SEQ ID NO: 1. 
11. A recombinant p65 protein prepared by expressing 
SEOID NO: 1 in a recombinant host cell in accordance with 
claim 10 and purifying the expressed protein away from 
total recombinant host cell components. 
12. A nucleic acid molecule comprising a sequence region 
that consists of at least a 20 nucleotide long continuous 
Sequence that hybridizes under Stringent conditions to a 
contiguous sequence of SEQ ID NO: 1 from nucleic acid 
position 1 to nucleic acid position 1035. 
13. A method for detecting the presence of nucleic acids 
encoding for the p65 oncofetal protein in a mammalian 
Sample, comprising the Steps of 
a. obtaining nucleic acids from a Sample Suspected of 
containing the p65 oncofetal protein; 
b. isolating nucleic acids from Said Sample; 
c. contacting Said nucleic acids with a nucleic acid Seg 
ment of at least a 20 nucleotide long continuous 
Sequence that hybridizes under Stringent conditions to 
a contiguous sequence of SEQ ID NO: 1 from nucleic 
acid position 1 to nucleic acid position 1035 under 
conditions effective to allow hybridization of substan 
tially complementary nucleic acids, and 
detecting the hybridized complementary nucleic acids 
thus formed. 
14. The method of claim 13, wherein the sample nucleic 




15. The method of claim 13, wherein the sample nucleic 
acids are Separated from a cell prior to contact. 
16. The method of claim 15, wherein the sample nucleic 
acids are DNA. 
17. The method of claim 15, wherein the sample nucleic 
acids are RNA. 
18. A method to aid in the diagnosis of a cancer which 
produces a 65 kD tumor-associated protein in a mammal 
comprising: 
a. providing a Sample of nucleic acids from the biological 
material of Said mammal wherein the biological mate 
rial is plasma, Serum, urine, Saliva, cystol fluid, ascites 
or tissue; 
b. contacting Said Sample nucleic acids with a nucleic acid 
Segment of at least a 20 nucleotide long continuous 
Sequence that hybridizes under Stringent conditions to 
a contiguous sequence of SEQ ID NO: 1 from nucleic 
acid position 1 to nucleic acid position 1035 under 
conditions effective to allow hybridization of Substan 
tially complementary nucleic acids, and 
c. detecting the hybridized complementary nucleic acids 
thus formed. 
19. A method for detecting p65 oncofetal protein in a 
mammalian Sample comprising the Steps of: 
a. preparing an antibody preparation to a purified protein 




b. Selecting an antibody Set that is immunoreactive to p65 
protein, and not immunoreactive to estrogen receptor 
protein; 
c. providing a mammalian Sample comprising plasma, 
Serum, urine, Saliva, cystic fluid, ascites, or tissue; 
d. contacting Said Sample and Said antibody Set to form an 
immunoconjugate; and 
e. detecting Said immunoconjugate. 
20. The method of claim 19, wherein said antibody 
preparation is polyclonal, monoclonal, or monospecific. 
21. The nucleic acid molecule of claim 12, further defined 
as having the sequence of SEQ ID NO: 1. 
22. The method of claim 13, wherein the nucleic acid 
segment has the sequence of SEQ ID NO:1. 
23. A method for detecting p65 oncofetal protein in a 
mammalian Sample comprising the Steps of: 
a. preparing an antibody preparation to the N-terminal 
half of the p65 protein; 
b. providing a mammalian Sample comprising plasma, 
Serum, urine, Saliva, cystic fluid, ascites, or tissue; 
c. contacting Said Sample and Said antibody preparation to 
form an immunoconjugate; and 
d. detecting Said immunoconjugate. 
24. The method of claim 23, wherein said antibody 
preparation is polyclonal, monoclonal, or monospecific. 
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